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Summary.-It has previously been shown that rat embryo cells treated in vitro with
3-methylcholanthrene (MCA) elicit antibodies in syngeneic rats which react speci-
fically against established MCA-induced sarcomas. To examine the possibility that
clonal amplification of one or a few antigenic, preneoplastic clones is responsible for
the previously observed specific antibody responses, MCA-treated rat embryo cells
have been subjected to 150 Gy of y-irradiation before injection into host animals. The
resulting antisera were screened for reactivity against a panel of established syn-
geneic tumours by membrane immunofluorescence and an isotopic antiglobulin test.
Apositivereactionwasobservedbetweenanantiserumpoolraisedagainsty-irradiated
MCA-treated cellsandthecellsofanimmunogenicspontaneousmammarycarcinoma.
Antiserum to y-irradiated control (acetone-treated) cells was negative. Thus y-
irradiation of carcinogen-treated cells before injection failed to abolish specific
antibodyresponses inimmunized rats.Toinvestigatefurthertherelationships between
cell-carcinogen interaction, neoantigen induction and malignancy, the cells of a
non-immunogenic, spontaneous mammary carcinoma were treated with MCA in
vitro, and antisera against treated and untreated cells were tested against a panel of
established tumours. A positive membrane-immunofluorescence reaction was ob-
tained with an antiserum to MCA-treated cells, but not to untreated cells against an
aminoazodye-induced hepatoma, indicating that the previously non-immunogenic
mammary carcinoma cells had acquired new antigenic specificities as a conse-
quence of carcinogen treatment.
NEOPLASTIC TRANSFORMATION by chemi-
cal carcinogens often leads to the expres-
sion in the transformed cell ofneoantigens
which are not detectable on normal cells.
Classically, these antigens have been
defined in tumours by experiments in
which syngeneic hosts are pre-immunized
with tumour prevented from progressive
growth by surgical extirpation or attenua-
tion, followed by challenge with viable
tumour cells sufficient to cause progressive
growth in controls. Antigens detected by
a rejection response in such assays are
termed tumour-associated rejection anti-
gens (TARA) or tumour-associated trans-
Correspondence to: Dr M. J. Embleton.
plantation antigens (TATA). Cell-surface-
associated antigens are also detectable on
many chemically induced tumours by
serological assays involving sera from
immune donors (Baldwin et al., 1979) and
in general these have the same distribution
and selectivity as TARAs. In spite of this
concordance of expression, it cannot with
certainty be stated that serologically
detected antigens are identical with
TARAs, and they are therefore better
designated separately as tumour-cell
surface antigens (TCSA). However, since
TARA and TCSA exist in parallel, the
general features of their expression areJ. G. REEVE, M. J. EMBLETON AND R. W. BALDWIN
common. Collectively, tumour neoantigens
arise as a consequence of the interaction
between cell and carcinogen (Embleton
& Heidelberger, 1972, 1975) and appear to
be closely associated with tumorigenicity
(Mondal et al., 1971). However, despite
this close association, their acquisition
appears not to be an essential step in
neoplastic transformation, since many
chemically induced tumours and most
spontaneous animal tumours have no
neoantigens detectable by transplantation
tests (Baldwin et al., 1979; Baldwin &
Embleton, 1969; Hewitt et al., 1976). On
the basis of these observations, the rela-
tionship between cell-carcinogen inter-
action, neoantigen induction and neo-
plastic transformation are unclear. It
has recently been reported that rat embryo
cells treated in vitro with 3-methyl-
cholanthrene (MCA) acquire new cell-
surface antigenic specificities which cross-
react specifically and reproducibly with
counterparts on certain established chemi-
cally induced tumours (Embleton &
Baldwin, 1979). These findingssuggestthat
TCSAs of chemically induced tumours
are not unique, but may be reproduced on
carcinogen-treated cells or their progeny
after only a short period of exposure to
carcinogen. MCA-treated rat embryo cells
failed to undergo neoplastic transforma-
tion during the course of these studies, as
evidenced by the absence of macroscopic
tumours in immunized animals, and extra-
nuclear membrane preparations of MCA-
treated cells did not induce antibody
responses, indicating that new surface
antigens were probably not produced
during the short exposure to carcinogen.
Thus it seems most likely that neoantigen
specificities are acquired during some stage
of preneoplastic development occurring
after injection of MCA-treated cells into
the host. In the present study we have
investigated the possibility that clonal
amplification of one, or a few, antigenic
clones after injection ofMCA-treated cells
into the host animal is responsible for the
observed specific antibody responses. Car-
cinogen-treated rat embryo cells were
therefore subjected to y-irradiation before
immunization and the resulting antisera
were screened against a panel of estab-
lished rat tumours.
In order to investigate further the rela-
tionship between cell-carcinogen interac-
tion, neoantigen expression and malignant
transformation we have also treated the
cells of non-immunogenic spontaneous
mammary carcinoma in vitro with MCA,
and have looked for specific antibody
responses in syngeneic rats immunized
with these cells, to determine whether
carcinogen treatment would induce neo-
antigenexpression incellswhicharealready
neoplastic.
MATERIALS AND METHODS
Rats.-Inbred WAB/Not rats were used
both for immunological studies and as donors
of embryos and syngeneic tumours.
Carcinogen treatment.-Single-cell suspen-
sions were prepared from minced 17-19-day
rat embryos and from mammary carcinoma
Sp15 by repeated treatment with 0 25%
trypsin (Difco). Mammary carcinoma Spi5
was of spontaneous origin and is non-
immunogenic in syngeneic rats. Between
5 x 107 and 10 viable embryo or tumour cells
were plated in 100mm non-tissue-culture
Petri dishes (Oxoid) in 10 ml Eagle's MEM
supplemented with calf serum (10%), peni-
cillin (200 i.u./ml), streptomycin (100 ,ug/ml)
and either 0-500 acetone or 0-500 acetone
containing 2 mg/ml 3-methylcholanthrene
(MCA, Sigma). The final concentration of
MCA in the medium was 10 ,ug/ml. Dishes
were incubated for 18 h at 37°C in an atmos-
phere of5% CO2 in air and the cells harvested
by aspiration and rinsing. Cells were subse-
quently washed x 6 in Hanks' balanced salt
solution (HBSS) and recounted.
y-irradiation and immunization.-Before
injection into host animals, rat embryo and
Spl5 tumour cells were exposed to 150 Gy
y-irradiation from a cobalt-60 source. The
cells were then injected i.p. into syngeneic
male rats, each rat receiving the cellular
contents of one dish (2-5 x 107 viable cells).
Four injections were given at 10-day inter-
vals and the rats bled by cardiac puncture
7 days after the 4th injection. Serum was
prepared from clotted blood, and samples
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from rats receiving identical treatments were
pooled and stored at - 20°C in small aliquots.
In another experimental design, mammary
carcinoma Spl5 cells were treated in vitro
with either MCA or acetone as previously
described, cells were washed x 6 and 1 ml
of a suspension containing either 106 viable
MCA- or acetone-treated Spl5 cells was
injected i.p. into syngeneic animals; all rats
developed tumours within 3 weeks. A single-
cell suspension of each tumour was then pre-
pared by trypsinization, and 1 ml containing
106 cells of this was injected i.p. into syn-
geneic rats. Each tumour cell line was subse-
quently maintained in vitro by successive i.p.
transplantation of 106 tumour cells. In this
way 6 tumour lines were prepared, 3 derived
from Spl5 cells treated in vitro with MCA and
3 from Spl5 cells treated in vitro with acetone.
To investigate whether tumour lines de-
rived from Spl5 cells treated in vitro with
MCA had acquired immunogenic potential
(new antigenic specificities), an antiserum was
raised against each tumour line in the follow-
ing way: at each in vivo passage, afterremoval
of 106 cells for line maintenance, the remain-
der of the tumour single cell suspension was
exposed to 150 Gy of y-irradiation and
1-5 x 107 cells were injected i.p. into each of
7 syngeneic rats. This procedure was repeated
x 4, animals being bled by cardiac puncture
7 days after administration of the final
inoculum. Serum was prepared and stored as
previously described.
Membrane immunofuorescence test.-Sera
were tested for reactivity against a range of
WAB/Not rat tumours using a membrane
immunofluorescence test performed on viable
suspended cells (Baldwin et al., 1971). Target
tumours included an immunogenic spontane-
ous mammary carcinoma (Sp4), 3 amino-
azodye-induced hepatomas (D23, D30 and
D192A) and 3 MCA-induced sarcomas (Mc7,
Mc106B and Mc107B). Normal rat serum was
used as background control and reactivity to
MCA-treated cells was expressed as a
fluorescence index (FI) defined as:
00 target cells 0% target cells
unstained by - unstained by
normal rat serum test serum
00 target cells unstained by normal rat
serum
A Fl 0-30 was taken to indicate a positive
reaction (Baldwin et al., 1971).
The specificity of any positive reactions
was examined by a series of absorption tests.
Aliquots of serum were absorbed for 2 h at
4°C with tumour cells at a density of 108
cells/ml of serum. Cells were removed by
centrifugation and the absorbed sera were
tested for reactivity against selected target
cells. A reduction of more than 50% in Fl
with absorbed serum compared with that
obtained with unabsorbed serum was taken
to represent a significant degree of antibody
absorption.
Isotopic antiglobulin te8t.-Sera were also
tested for reactivity against certain tumour
target cells, using an isotopic antiglobulin test
(Williams et al., 1977). Dilutions of each
antiserum were prepared in HBSS containing
1% bovine serum albumin (BSA, Sigma).
100 ,ul aliquots of diluted antiserum were
incubated in triplicate with 105 tumour
target cells for 1 h on ice. Cells were washed
x 3 in HBSS containing 0.1% BSA and
incubated for 1 h on ice with 50 1l of 1%
BSA containing 1251-labelled sheep F(ab)2
anti-rat IgG. Each cell suspension received
7 ng protein, to give between 2 x 105 and
3 x 105 ct/min. Cells were washed x 6 in
HBSS containing 01% BSA, centrifuged
and the cell pellets counted in a gamma
counter.
The mean ct/min obtained with antisera
raised to MCA-treated cells were compared
withthe mean ct/minwithantiseratoacetone-
treated cells, and with normal rat serum. Data
were analysed by a single-classification ana-
lvsis of variance.
Metabolism of 3H-MCA by Spl5 mammary
carcinoma cells.-The ability of mammary
carcinoma Spl5 cells to take up and metabo-
lize MCA was determined as described by
Diamond et al. (1968). Mammary carcinoma
SpI5 cells (5 x 107) were plated into 100mm
Oxoid dishes in 10 ml medium containing
10 jug/ml MCA, of which 5 ng/ml was 3H-
MCA (0 5 ,uCi/ml). Cells were incubated at
37°C for 18 h, centrifuged and the supernatant
collected. The cell pellet was washed x 3,
solubilized in 3M KOH and diluted in 5 vols
ofmethanol before assaying for radioactivity.
The supernatant was extracted in a mixture
of 20 vols of chloroform: methanol (2:1 v/v)
and 4 vols of water. The aqueous and organic
solvent fractions of the extraction mixture
were separated and assayed for activity in a
/ counter.
After 18 h of incubation, 5 x 107 cells had
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bound, on average, 6.6% 3H-MCA (646 ,g/
5 x 107 cells). At zero time, 14% of the 3H-
MCA was recovered in the aqueous phase,
after chloroform/methanol extraction. Within
18 h of adding 3H-MCA to the cells, 28% of
the label in the medium was recoverable in
the aqueous phase of the extraction mixture.
RESULTS
Antisera raised against cells treated in vitro
with MCA or acetone
As shown in Tables I and II, none of
the sera raised against either irradiated
acetone-treatedratembryo cellsoracetone-
treated mammary carcinoma Spl5 cells
TABLE II.-Membrane immunofluorescence
reactions against rat tumours bysyngeneic
antiserum to y-irradiated MCA-treated
mammary carcinoma Spl5 cells
Target cellst
Hepatoma D23
D30
D192A
Sarcoma Mc7
Mc106B
Mc1O7B
Carcinoma Sp4
Sp15§
Mean Fl (± s.d.)
Antisera to Spl5 cells
treated with:
MCA Acetone
(A4979) (A4980)
0-13 +0-02 0 01+0 01
0-21 + 0-18 0 05+ 0 04
0-32 + 0 05 0-08 + 0-06
0-10 +0-01 0-10+0-01
0-06 + 0-08 0 00
0-15 + 0-13 0-12+ 0-16
0 11 +0-12 0-09+0-12
0 11 0-02
TABLE I.-Membrane immunoftuorescence
reactions against rat tumours by anti-
serum to MCA-treated, irradiated embryo
cells
Mean Fl (±s.d.)
Antisera to irradiated
embryo cells treated with:
Target cellst
Hepatoma D23
D30
D192A
Sarcoma Mc7
Mc106B
Mc1O7B
Mammary
carcinoma Sp4
Spi5
MCA
(A5104)
0-12 + 0-02
0-02 + 0.01
0-06 + 0-02
0-18 + 001
0.00* + 0.00
0-23 + 0 01
Acetone
(A5105)
0.00*
0-02 + 0-02
0.00*
0.00*
0.00
0*00
034§+0.14 009+001
0.03T 0.13¶
t Hepatomas were originally induced by oral
4-dimethylaminoazobenzene. The sarcomas were
induced by s.c. injection of 3-methylcholanthrene,
and breast carcinoma Sp4 was spontaneous.
* Values numerically lower than zero.
§ P < 0-025.
Results from one test only.
produced significant membrane immuno-
fluorescence against the tumour target
cells studied, indicating that these cells
per se did not induce antibody responses in
syngeneic rats detectable by the mem-
brane-immunofluorescence test. However,
when antisera to y-irradiated MCA-
treated cells were tested, two positive
reactions were noted. Antiserum A5104,
raised against irradiated MCA-treated rat
t See Table I.
t P < 0 0005 derived from 5 independent tests.
§ Results from one test only.
embryo cells, was consistently positive in
each of 3 independent tests against an
immunogenic spontaneously arising mam-
mary carcinoma, Sp4, and antiserum
A4979, raised against MCA-treated mam-
mary carcinoma Spl5 cells, gave sig-
nificant reactions against an aminoazodye-
induced hepatoma, D192A. In the latter
case 5 independently repeated tests were
consistently positive. In both cases the
mean difference in the percentage of cells
stained by normal rat serum or acetone
control serum and the antiserum to MCA-
treated cells was statistically significant as
determined by Student's t test. All the
negative combinations were repeated x 3,
with consistently negative results.
The relatively high mean Fl of 0-21
which was obtained when A4979 was
reacted with hepatoma D30 is considered
spurious, since a positive reaction was
obtained in only 1 ofthe 3 tests performed.
The specificity ofthe observed antibody
responses was confirmed by the absorption
tests shown in Table III. Thus the reac-
tivity of serum A5104 against mammary
carcinoma Sp4 could be removed by
absorption with Sp4 cells, but not by
absorption with either hepatoma D23
or sarcoma Mc7 cells. Similarly the reac-
tivity of serum A4979 against hepatoma
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TABLE III.-Absorption of anti-tumour
antibodies from antisera to MCA-treated
rat embryo and MCA-treated mammary
carcinoma Sp15 cells
Target
cells Serum*
% Fl
Absorbing reduc-
cellst FL tion
Sp4 Anti-MCA-treated None
embryo cells D23
(A5104) Mc7
Sp4
D192A Anti-MCA-treated None
Sp15 cells Mc106B
(A4979) D192A
0-36
0 30
0-32
0*00
0-41
0 35
0-06
17
12
100
15
85
* Antisera raised against y-irradiated cells.
t Serum was absorbed for 2 h at 4°C using 108
cells/ml of serum, which were removed by centri-
fugation at 10,000 g for 10 min.
TABLE V.-Absorption of Sp4 reactivity
from syngeneic antisera to irradiated
MCA-treated rat embryo cells
Antiserum raised
against 4
Irradiated MCA-
treated embryo cells
Normal rat serum
Binding of 1251
sheep F(ab)2
anti-rat IgG
Absorption (Mean ct/min +s.e.)
Sp4
D23
1006 + 74
709 + 26
1005+ 38
475+31
reduction in the mean ct/min, but not by
absorption withthe cells ofhepatoma D23,
thus confirming the findings from mem-
brane immunofluorescence.
D192A was removed by absorption with
D192A cells but not by absorption with
the cells ofsarcoma Mc106B.
The positive membrane-immunofluores-
cence reaction between A5104 and Sp4
and the specificity of this reaction have
been confirmed using the isotopic anti-
globulin test. Thus in 3 independent tests
the mean ct/min when A5104 was reacted
with Sp4 target cells was significantly
higher than that obtained with either the
acetone control antiserum (A5105) or
normal rat serum (Table IV). Both anti-
sera A5104 and A5105 failed to react
significantly with 5 other syngeneic tu-
mours tested (D23, D192A, Mc7, Mc106B
and Mc107B). Table V shows that the
reactivity of antiserum A5104 against
Sp4 cells was removed by absorption with
Sp4 cells, as indicated by a significant
Antisera raised against tumour lines
derivedfrom Spl5 cells treated in vitro with
MCA or acetone
When antisera to Spi5 tumour lines
derived from cells treated in vitro with
acetone were tested against a panel of
established chemically induced and spon-
taneous tumours (including mammary
carcinoma Sp15), no positive membrane-
immunofluorescence reactions were noted
(Table VI). Furthermore, antisera raised
to y-irradiated, untreated Spi5 cells also
failed to give positive membrane-immuno-
fluorescence reactions against either Sp15
or other tumour cells tested in this study.
However, a positive membrane-immuno-
fluorescence reaction was observed be-
tween one antiserum raised against a
tumour line derived from Sp15 cells
TABLE IV.-Antiserum reactions against mammary carcinoma Sp4 target cells as
determined by an isotopic-antiglobulin test*
Binding of 125I sheep F(ab)2 anti-rat IgG
(Mean ct/min+ s.e.)
Antisera raised against
Irradiated MCA-treated embryo cells (A5104)
Irradiated acetone-treated cells (A5105)
Normal rat serum
Dilution
1/2
1/5
1/2
1/5
1/2
1/5
Test 1
1006+ 74
591+ 61
615+ 39
485+ 170
475+ 31
467+ 27
Test 2
5322 + 359
3710+ 36
2614 + 22
2673 + 149
852+ 161
1114+ 77
Test 3
2098 + 186
1455+ 59
1131+ 104
1018+ 44
710+ 15
861+ 9
* See Materials and Methods.
Data were analysed by single-classification analysis of variance: the mean ct/min with A5104 was
significantly higher than that obtained with either A5105 or normal rat serum (P <0-01).
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Spl5 cells treated in
Mean Fl (+ s.d.)
Antisera to SpI5 tumours
derived from cells treated
in vitro with
MCA Acetone
(A5764) (A5763)
0-00
0-00
0-01 + 0.00
000
0-19 + 0-06
0-00
0-00
0 01 + 0-14
0-01 + 0.01
0-09 + 0-07
carcinoma Sp4 0-63+0-5T 0-16+0-05
Spl5§ 0 00 0 00
t See Table I.
t P < 0 005 derived from 4 independent tests.
§ Results from one test only.
treated in vitro with MCA, and the cells
of an immunogenic spontaneous mam-
mary carcinoma, Sp4 (Table IV). This
antiserum, A5764, was consistently posi-
tive in each of 3 independent tests, and
the specificity of the reactions was con-
firmed by a series of absorption tests
(Table VII). Thus the reactivity of serum
A5764 against mammary carcinoma Sp4
was removed by absorption with Sp4 cells,
but not by absorption with the cells of
hepatoma D23, sarcoma Mc7 or carcinoma
Sp15.
TABLE VII.-Absorption of anti-tumour
antibodies from antisera to tumours
derived from mammary carcinoma Spl5
cells treated in vitro with MCA
Target
cells Serum*
Sp4 Anti-MCA/Sp15
tumour (A5764)
Absorbing
cellst FI
None
Mc7
D23
Spi5
Sp4
0-71
0-52
0-54
0-65
0-12
% FI
reduc-
tion
27
24
8
83
* Raised against y-irradiated cells of tumours
derived from SpI5 cells treated in vitro with MCA.
t Serum absorbed for 2 h at 4°C using 108 cells/ml,
which were removed by centrifugation at 10,000 g
for 10 min.
The positive reaction between anti-
serum A5764 and Sp4 was also confirmed
by the isotopic antiglobulin test. In 2
independent tests the mean ct/min when
A5764 was reacted against Sp4 target cells
was significantly higher than that obtained
TABLE VIII.-Reactivity against mammary
carcinoma Sp4 by antiserum to tumour
derived from mammary carcinoma Spl5
cells treated in vitro with MCA
Serum*
Anti-MCA/Spl5-treated
tumour line (A5764)
Anti-AC/Spl5 (A5763)
Normal rat serum
Binding of 1251 sheep
F(ab)2 anti-rat IgG to
serum-treated Sp4 cells
Test 1 Test 2
4541 + 575
1222 + 98
1479 + 135
1111 +97
667+ 59
517 + 42
Data were analysed by a single-classification
analysis of variance: the mean ct/min when A5764
was reacted against Sp4 target cells is significantly
higher than that obtained with either acetone
control serum (A5763) or normal rat serum (P < 0-01).
with either the acetone control serum,
A5763, or normal rat serum (Table VIII).
The4remainingantiseradirectedagainst
Spi 5 tumour lines derived from cells
treated in vitro with MCA or acetone failed
to give positive reactions, as determined
by the membrane-immunofluorescence test
and the isotopic-antiglobulin test, against
either Sp4 or the chemically induced
tumours included in this study.
One explanation for the reactivity
between antisera raised to carcinogen-
treated cells and certain chemically in-
duced or spontaneous tumours is that it
is due to the presence of natural antibody
rather than to the induction ofneoantigens
on carcinogen-treated cells. This possi-
bility was examined by screening both
D192A and Sp4 against 10 samples of
serum from normal rats. Reactivity of
the normal rat serum samples was assayed
with both membrane immunofluorescence
and the isotopic antiglobulin tests. How-
ever, no reactivity was found between the
target cells and the samples of normal rat
serum by either method.
TABLE VI.-Membrane-immunoftuores-
cence reactions against rat tumours by
antiserum to tumours derived from main-
mary carcinoma
vitro with MCA
Target cellst
Hepatoma D23
D192A
Sarcoma Mc7
Mc107B
Mc109B
Mammary
814ANTIBODIES TO MCA-TREATED CELLS
DISCUSSION
It has previously been shown that rats
immunized with embryo cells treated in
vitro with MCA develop antibodies which
react specifically and reproducibly with
certain chemically induced rat tumours
(Embleton & Baldwin, 1979). On the basis
of this finding it seems highly likely that
the TCSAs of chemically induced tumours
are not unique, but can be reproduced on
carcinogen-treated cells or their progeny
after a short period of exposure to carcino-
gen. In the present study, an antiserum
raised to y-irradiated MCA-treated rat
embryo cells reacted specifically and re-
producibly with the cells of an immuno-
genic spontaneous mammary carcinoma,
Sp4. This finding suggests that the poten-
tial repertoire of neoantigen specificities
which may be expressed on rat embryo
cells as a result of carcinogen treatment is
not restricted to those antigenic specifici-
ties demonstrable as TCSA on chemically
induced tumours, but also includes anti-
gens which cross-react with counterparts
on the cells of a spontaneous tumour.
It has been postulated that the new
antigens induced on carcinogen-treated
cells arise during some stage of pre-
neoplastic development (Embleton &
Baldwin, 1979). Thus it is possible that
the specific antibody responses observed
in rats immunized with carcinogen-treated
cells develop as one or few preneoplastic
antigenic clones undergo amplification
after injection into the host animal as a
result offurther in vivo development. How-
ever, in the present study, y-irradiation of
carcinogen-treated cells before injection
into host animals failed to abolish specific
antibody responses in immunized animals.
This finding makes clonal amplification
of preneoplastic antigenic clones an un-
likely requirement for the generation of
the observed specific antibody responses,
since after y-irradiation cells are incapable
of repeated division. An alternative hypo-
thesis is that neoantigens appear through
early interactions of carcinogen with
target cells by a mechanism not involving
multiple cell divisions, and that in car-
cinogenesis such antigens persist through
all stages of progression to malignancy.
This view is supported by the observation
that skin papillomas induced with MCA
express neoantigens with specificities
identical to TARAs on subsequent skin
carcinomas (Lappe, 1969).
The results obtained when the cells of
mammary carcinoma Spl5 were incubated
in the presence of 3H-MCA indicate that
these cells are able to bind and metabolize
MCA under the culture conditions pre-
viously described. Also an antiserum raised
to MCA-treated SpI5 cells reacted con-
sistently and reproducibly with the cells
of an aminoazodye-induced hepatoma,
D192A. One interpretation of these find-
ings is that as a result of carcinogen treat-
ment these previously non-immunogenic
cells have acquired neoantigen specificities
which are absent from untreated cells, and
if so, that, as previously suggested by
Embleton & Baldwin (1979), chemically
induced neoantigens are not specific for a
particular carcinogen. Furthermore, these
results indicate that neoantigen speci-
ficities can be induced on already neo-
plastic cells.
In the second experimental design, an
antiserum raised against a tumour derived
from Sp15 cells treated in vitro with MCA
reacted consistently and reproducibly
with the cells ofthe spontaneous immuno-
genic mammary carcinoma, Sp4. The
corresponding tumour derived from
acetone-treated Spl5 cells failed to elicit
Sp4 antiserum reactivity, suggesting that
the observed reactivity of antiserum
A5764 with Sp4 cells arose through the
in vitro treatment of SpI5 cells with MCA.
One interpretation of this finding is that
the carcinogen-treated Sp15 tumour cells
have acquired an antigenic specificity
which is the same as, or similar to, the
TCSA of Sp4.
Since the experimental design used in
this study makes it possible to reclaim
carcinogen-treated cells as overt tumour,
following injection into host animals, we
should now be able to test directly whether
or not cells treated in vitro with carcinogen
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do indeed express TCSA, and perhaps
whether TCSA and TARA are identical.
Previous studies have shown that car-
cinogen-treated rat embryo cells, while
capable of expressing neoantigens which
cross-react with their counterparts on
certain established tumours, failed to
manifest malignancy during the course of
these studies (Embleton & Baldwin, 1979).
This observation, together with the
apparent induction of neoantigens on
already neoplastic cells, may indicate that
the induction ofnew antigenic specificities
by MCA is not necessarily related to the
change from the normal to the neoplastic
phenotype.
This work was supported by the Cancer Research
Campaign, U.K.
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